In general, Down syndrome samples and normal or other mentally retarded groups of similar mental or chronological age have been compared at a single point in time. Medical practitioner perceives the condition more of a genetic disorder than a pathological disease. Guided by the principle of naturalism and existence, the health care practitioners further view the person with Down syndrome in a biological means rather than the sociological and physical morphology in order to deliver the rightful care (Rogers and Coleman, 2002 p.
8). To some point of logic, these practitioners possess the capacity to analyze and predetermine the conditions of these individuals. Most often than not, medical field comprehends the totality of the Down syndrome’s behavior, attitude and perception towards their environment. However, the burden takes in since, the actual condition still possess no cure, but only therapeutic procedurals and pharmacologic therapy for symptoms.
In addition, genetic preview is the prime intervention that they can do in order to prevent further progression of the condition, or the conception itself. Genetic tests involve laboratory analyses of chromosomes, genes, or gene products (enzymes of proteins) to detect a gene alteration that can be the etiological agent or is likely to induce a specific genetic disorder or condition. Genetic testing can be DNA- or RNA-based, chromosomal, or biochemical in nature and procedurals, which possess various advantage and disadvantages.
Genetic tests are currently used to predict risk of disease, to screen newborns for genetic conditions, to screen pregnant women for risk of genetic conditions, fore prenatal or clinical diagnoses or prognoses, and to direct clinical care. The procedures of chorionic villus sampling and amniocentesis are the primary genetic testing involved in the detection of Down syndrome (Jenkins and Lea, 2004 p. 75).